Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.68 |
| ▸ | RAB9A | P51151 | 8/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | F7 | P08709 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227743 | 0.85 | NPC1 (0.78) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7702980 | 0.83 | NPC1 (0.55) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL172216 | 0.82 | NPC1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30561047 | 0.82 | NPC1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30634854 | 0.82 | NPC1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL297468 | 0.81 | RAB9A (0.67) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1224262 | 0.81 | ALDH1A1 (0.61) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| Water SCHEMBL9817804 | 0.80 | NPC1 (0.95) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL20503145 | 0.80 | NPC1 (0.55) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL12603044 | 0.80 | CDK1 (0.66) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10980798-B2 | Pharmaceutical compositions of hydrophobic camptothecin derivatives | TAIWAN LIPOSOME COMPANY, LTD. (TW) | 2021-04-20 | — | — | US | claimed |
| US-20190321356-A1 | PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES | TAIWAN LIPOSOME CO., LTD. (TW) | 2019-10-24 | — | — | US | claimed |
| EP-3244930-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIV SOUTHERN CALIFORNIA (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260083685-A1 | METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260069587-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-12514828-B2 | Methods of permeabilizing the blood brain barrier | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-01-06 | — | — | US | disclosed |
| US-12508275-B2 | Neomycin based compounds, and pharmaceutical use thereof | UNIVERSITÉ COTE D'AZUR (FR) | 2025-12-30 | — | — | US | disclosed |
| EP-4656641-A2 | METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL | University of Southern California (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250332262-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| US-12419832-B2 | Intratumoral delivery of bortezomib | COGNOS THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250270293-A1 | SCAFFOLD PROTEINS | AVACTA LIFE SCIENCES LIMITED (GB) | 2025-08-28 | — | — | US | disclosed |
| EP-0950054-A1 | SUBSTITUTED HETEROCYCLES AS ANTI-TUMOR AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999041241-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999033824-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999031067-A1 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1998031673-A9 | TERBENZIMIDAZOLES USEFUL FOR MEDICAL THERAPY (TOPOISOMERASE INHIBITORS) | — | 1998-12-10 | — | — | WO | disclosed |
| WO-1998031673-A1 | TERBENZIMIDAZOLES USEFUL FOR MEDICAL THERAPY (TOPOISOMERASE INHIBITORS) | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1998-07-23 | — | — | WO | disclosed |
| US-5770617-A | Terbenzimidazoles useful as antifungal agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770617-A | Terbenzimidazoles useful as antifungal agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1998012181-A1 | SUBSTITUTED HETEROCYCLES AS ANTI-TUMOR AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508275-B2 | Neomycin based compounds, and pharmaceutical use thereof | BRCA1, NTRK3, EGFR | NPC1 34/4885RAB9A 1891/4885ALDH1A1 2264/4885 |
| US-20190321356-A1 | PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES | TOP1, TOP2A, TOP2B | NPC1 1712/4885RAB9A 2123/4885ALDH1A1 3823/4885 |
| US-20250270293-A1 | SCAFFOLD PROTEINS | TRIM28, PHAX, KPNA1 | NPC1 2175/4885RAB9A 3331/4885ALDH1A1 4181/4885 |
| US-20260069587-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | GCDH, PLIN3, PRPH | NPC1 1740/4885RAB9A 2797/4885ALDH1A1 400/4885 |
| US-20250332262-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PDE3A, PDE3B, PDE5A | NPC1 2439/4885RAB9A 644/4885ALDH1A1 205/4885 |
| US-20260083685-A1 | METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER | CD4, EPCAM, ICOS | NPC1 117/4885RAB9A 1366/4885ALDH1A1 1230/4885 |
| US-10980798-B2 | Pharmaceutical compositions of hydrophobic camptothecin derivatives | TOP1, TOP2A, TOP2B | NPC1 1712/4885RAB9A 2123/4885ALDH1A1 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.